A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis

Figure 3

Clinical remission rate and clinical response rate at 2 months. (a) Clinical response rate at 2 months was 81.3% in the infliximab group and 68.1% in the tacrolimus group, without a significant difference between the two groups. (b) Clinical remission rate at 2 months was 68.8% in the infliximab group and 55.3% in the tacrolimus group, without a significant difference between the two groups.

(a) Clinical response rate at 2 months

(b) Clinical remission rate at 2 months